| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 144 | 2023 | 5511 | 12.180 |
Why?
|
| Skin Neoplasms | 132 | 2023 | 5692 | 11.280 |
Why?
|
| Proto-Oncogene Proteins B-raf | 22 | 2022 | 2043 | 2.840 |
Why?
|
| Dysplastic Nevus Syndrome | 9 | 2018 | 63 | 2.780 |
Why?
|
| Melanocytes | 14 | 2022 | 515 | 2.240 |
Why?
|
| Nevus, Pigmented | 9 | 2016 | 219 | 2.230 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 8 | 2022 | 252 | 2.170 |
Why?
|
| Ubiquitin Thiolesterase | 7 | 2019 | 449 | 1.990 |
Why?
|
| GTP Phosphohydrolases | 7 | 2021 | 508 | 1.860 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 15 | 2018 | 705 | 1.790 |
Why?
|
| Germ-Line Mutation | 22 | 2020 | 1788 | 1.740 |
Why?
|
| Tumor Suppressor Proteins | 13 | 2019 | 2850 | 1.620 |
Why?
|
| Neoplastic Syndromes, Hereditary | 6 | 2018 | 241 | 1.590 |
Why?
|
| Carcinoma, Basal Cell | 8 | 2023 | 545 | 1.580 |
Why?
|
| Genes, p16 | 12 | 2016 | 157 | 1.480 |
Why?
|
| Uveal Neoplasms | 5 | 2019 | 310 | 1.470 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 5 | 2019 | 68 | 1.370 |
Why?
|
| Skin Diseases | 7 | 2017 | 1066 | 1.350 |
Why?
|
| Dermatology | 9 | 2020 | 872 | 1.170 |
Why?
|
| Eye Neoplasms | 4 | 2019 | 312 | 1.150 |
Why?
|
| Nevus | 6 | 2015 | 204 | 1.150 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2020 | 17446 | 1.080 |
Why?
|
| Early Detection of Cancer | 9 | 2020 | 3086 | 1.080 |
Why?
|
| Oncogenes | 3 | 2019 | 1265 | 0.970 |
Why?
|
| Mutation | 28 | 2022 | 29786 | 0.950 |
Why?
|
| Genetic Counseling | 7 | 2016 | 600 | 0.950 |
Why?
|
| Receptor, EphA2 | 3 | 2014 | 42 | 0.950 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2022 | 5534 | 0.940 |
Why?
|
| Cyclin-Dependent Kinase 4 | 12 | 2018 | 539 | 0.930 |
Why?
|
| Indoles | 4 | 2022 | 1839 | 0.930 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2021 | 776 | 0.900 |
Why?
|
| Cyclin-Dependent Kinases | 7 | 2018 | 671 | 0.890 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5172 | 0.870 |
Why?
|
| Molecular Targeted Therapy | 8 | 2021 | 2725 | 0.860 |
Why?
|
| Sulfonamides | 4 | 2022 | 1940 | 0.860 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 66 | 0.770 |
Why?
|
| Keratinocytes | 5 | 2023 | 799 | 0.770 |
Why?
|
| PTEN Phosphohydrolase | 8 | 2017 | 1142 | 0.770 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2021 | 8432 | 0.730 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 13693 | 0.730 |
Why?
|
| Membrane Proteins | 8 | 2021 | 7882 | 0.730 |
Why?
|
| Signal Transduction | 21 | 2020 | 23404 | 0.720 |
Why?
|
| Keloid | 1 | 2020 | 50 | 0.710 |
Why?
|
| Oxazoles | 1 | 2021 | 189 | 0.710 |
Why?
|
| Genes, Neoplasm | 2 | 2014 | 376 | 0.700 |
Why?
|
| Ultraviolet Rays | 6 | 2013 | 1060 | 0.700 |
Why?
|
| Phosphoric Monoester Hydrolases | 4 | 2004 | 431 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2023 | 4034 | 0.690 |
Why?
|
| Humans | 187 | 2023 | 744366 | 0.690 |
Why?
|
| Skin | 11 | 2019 | 4372 | 0.690 |
Why?
|
| Mutation, Missense | 4 | 2019 | 2566 | 0.660 |
Why?
|
| Sentinel Lymph Node Biopsy | 8 | 2022 | 710 | 0.650 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2011 | 392 | 0.630 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2017 | 2949 | 0.630 |
Why?
|
| Genetic Testing | 8 | 2010 | 3444 | 0.610 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 441 | 0.600 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 675 | 0.600 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2019 | 604 | 0.600 |
Why?
|
| Telomerase | 3 | 2019 | 730 | 0.600 |
Why?
|
| Skin Diseases, Genetic | 3 | 2012 | 41 | 0.590 |
Why?
|
| Genes, Tumor Suppressor | 8 | 2014 | 1097 | 0.570 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 2943 | 0.560 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 627 | 0.550 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 692 | 0.550 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2014 | 215 | 0.540 |
Why?
|
| Cell Cycle | 4 | 2019 | 2967 | 0.530 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2015 | 647 | 0.530 |
Why?
|
| Calcium Channels | 1 | 2019 | 622 | 0.530 |
Why?
|
| Genotype | 12 | 2021 | 12952 | 0.510 |
Why?
|
| Phenotype | 15 | 2022 | 16367 | 0.500 |
Why?
|
| Eczema | 1 | 2016 | 231 | 0.470 |
Why?
|
| Thiazoles | 1 | 2021 | 1483 | 0.460 |
Why?
|
| Hemangioma | 1 | 2019 | 738 | 0.460 |
Why?
|
| Bystander Effect | 1 | 2013 | 81 | 0.460 |
Why?
|
| SEER Program | 5 | 2006 | 1507 | 0.460 |
Why?
|
| Cell Line, Tumor | 15 | 2022 | 16690 | 0.460 |
Why?
|
| Pleural Neoplasms | 1 | 2018 | 607 | 0.440 |
Why?
|
| Pathology, Clinical | 3 | 2012 | 368 | 0.440 |
Why?
|
| Cell Proliferation | 8 | 2019 | 10483 | 0.440 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 74 | 0.430 |
Why?
|
| Mesothelioma | 2 | 2018 | 818 | 0.430 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2013 | 547 | 0.410 |
Why?
|
| Advisory Committees | 1 | 2016 | 775 | 0.410 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2016 | 1284 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2020 | 2455 | 0.400 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2703 | 0.400 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1758 | 0.400 |
Why?
|
| Collagen | 1 | 2020 | 2688 | 0.400 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 1340 | 0.390 |
Why?
|
| Apoptosis | 9 | 2019 | 9724 | 0.390 |
Why?
|
| DNA Mutational Analysis | 7 | 2019 | 4185 | 0.390 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 11031 | 0.380 |
Why?
|
| Tumor Cells, Cultured | 9 | 2019 | 6313 | 0.370 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2004 | 4554 | 0.370 |
Why?
|
| Imidazoles | 3 | 2013 | 1206 | 0.370 |
Why?
|
| Physical Examination | 1 | 2016 | 1237 | 0.360 |
Why?
|
| ras Proteins | 5 | 2008 | 1060 | 0.360 |
Why?
|
| Mohs Surgery | 2 | 2022 | 197 | 0.350 |
Why?
|
| Metagenome | 1 | 2013 | 418 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 1692 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3595 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 381 | 0.330 |
Why?
|
| Male | 65 | 2021 | 350115 | 0.330 |
Why?
|
| Pedigree | 9 | 2018 | 4642 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 2916 | 0.320 |
Why?
|
| Biopsy | 9 | 2021 | 6755 | 0.310 |
Why?
|
| Dermoscopy | 1 | 2008 | 56 | 0.310 |
Why?
|
| Neurofibromin 1 | 2 | 2021 | 196 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 4805 | 0.310 |
Why?
|
| Interferon-alpha | 3 | 2014 | 895 | 0.300 |
Why?
|
| Point Mutation | 3 | 2004 | 1624 | 0.300 |
Why?
|
| Calcium | 3 | 2019 | 5755 | 0.300 |
Why?
|
| Female | 68 | 2021 | 380193 | 0.300 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2019 | 139 | 0.300 |
Why?
|
| Human Genome Project | 1 | 2008 | 193 | 0.300 |
Why?
|
| Models, Genetic | 4 | 2010 | 3493 | 0.300 |
Why?
|
| X Chromosome Inactivation | 2 | 2010 | 224 | 0.290 |
Why?
|
| Xeroderma Pigmentosum | 2 | 2009 | 31 | 0.290 |
Why?
|
| Prognosis | 16 | 2023 | 29060 | 0.290 |
Why?
|
| Genes, ras | 3 | 2010 | 690 | 0.290 |
Why?
|
| Societies, Medical | 3 | 2020 | 3743 | 0.280 |
Why?
|
| Up-Regulation | 4 | 2020 | 4222 | 0.280 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 296 | 0.280 |
Why?
|
| Incidence | 13 | 2023 | 20952 | 0.280 |
Why?
|
| Dermatitis, Atopic | 1 | 2013 | 654 | 0.270 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 4463 | 0.270 |
Why?
|
| Melanoma, Experimental | 2 | 2007 | 561 | 0.270 |
Why?
|
| Tumor Burden | 3 | 2019 | 1915 | 0.270 |
Why?
|
| Receptor, Melanocortin, Type 1 | 5 | 2018 | 76 | 0.270 |
Why?
|
| Epigenesis, Genetic | 5 | 2022 | 3646 | 0.270 |
Why?
|
| Piperazines | 2 | 2013 | 2488 | 0.260 |
Why?
|
| raf Kinases | 1 | 2005 | 122 | 0.260 |
Why?
|
| Genetic Techniques | 2 | 2006 | 435 | 0.260 |
Why?
|
| Retinoblastoma Protein | 2 | 2005 | 705 | 0.250 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 3505 | 0.250 |
Why?
|
| Immunotherapy | 3 | 2021 | 4446 | 0.250 |
Why?
|
| Photosensitivity Disorders | 1 | 2004 | 78 | 0.250 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2009 | 587 | 0.240 |
Why?
|
| Animals | 30 | 2021 | 168768 | 0.240 |
Why?
|
| Endonucleases | 1 | 2007 | 380 | 0.240 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 1879 | 0.240 |
Why?
|
| Triage | 1 | 2011 | 977 | 0.240 |
Why?
|
| Middle Aged | 43 | 2021 | 213390 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 9240 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2003 | 1062 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2002 | 1381 | 0.230 |
Why?
|
| Nevus, Blue | 1 | 2003 | 38 | 0.230 |
Why?
|
| Neoplasms | 5 | 2020 | 21696 | 0.230 |
Why?
|
| Risk Assessment | 13 | 2023 | 23336 | 0.230 |
Why?
|
| Mice, SCID | 3 | 2019 | 2716 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 203 | 0.230 |
Why?
|
| Epidermis | 1 | 2006 | 528 | 0.230 |
Why?
|
| Neoplasm Metastasis | 3 | 2014 | 4851 | 0.220 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 5135 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2011 | 1783 | 0.220 |
Why?
|
| Transcription, Genetic | 4 | 2021 | 7721 | 0.220 |
Why?
|
| Boston | 7 | 2019 | 9312 | 0.220 |
Why?
|
| Mice | 15 | 2021 | 81201 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 719 | 0.220 |
Why?
|
| Genome, Human | 4 | 2017 | 4420 | 0.210 |
Why?
|
| Lymphatic Metastasis | 8 | 2019 | 2924 | 0.210 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 5856 | 0.210 |
Why?
|
| Molecular Biology | 2 | 2023 | 596 | 0.210 |
Why?
|
| Oxidative Stress | 1 | 2013 | 3084 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2016 | 4285 | 0.210 |
Why?
|
| SOXE Transcription Factors | 2 | 2022 | 57 | 0.210 |
Why?
|
| Hypopigmentation | 1 | 2002 | 41 | 0.210 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 9445 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2008 | 3751 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3921 | 0.200 |
Why?
|
| Hamartoma | 1 | 2003 | 238 | 0.200 |
Why?
|
| Aged | 27 | 2021 | 163288 | 0.200 |
Why?
|
| Hyperpigmentation | 2 | 2008 | 112 | 0.200 |
Why?
|
| Adult | 40 | 2021 | 214052 | 0.200 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 69 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3554 | 0.190 |
Why?
|
| Progesterone Congeners | 1 | 2000 | 42 | 0.190 |
Why?
|
| Cluster Analysis | 3 | 2016 | 2715 | 0.190 |
Why?
|
| Genomics | 2 | 2014 | 5717 | 0.180 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4208 | 0.180 |
Why?
|
| RNA, Messenger | 5 | 2022 | 13035 | 0.180 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 4 | 2004 | 335 | 0.180 |
Why?
|
| Pigmentation Disorders | 1 | 2000 | 101 | 0.180 |
Why?
|
| Primary Health Care | 1 | 2016 | 4557 | 0.180 |
Why?
|
| Nerve Growth Factors | 3 | 1992 | 574 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2015 | 323 | 0.180 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2000 | 163 | 0.180 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 730 | 0.170 |
Why?
|
| Sex Factors | 5 | 2019 | 10400 | 0.170 |
Why?
|
| Cell Survival | 3 | 2014 | 5882 | 0.170 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 1149 | 0.170 |
Why?
|
| Biomedical Research | 3 | 2021 | 3309 | 0.170 |
Why?
|
| Laser Therapy | 4 | 2009 | 1072 | 0.170 |
Why?
|
| Lipomatosis, Multiple Symmetrical | 1 | 1998 | 9 | 0.170 |
Why?
|
| Tissue Embedding | 1 | 2019 | 43 | 0.170 |
Why?
|
| Risk Factors | 17 | 2020 | 72296 | 0.170 |
Why?
|
| Keratoacanthoma | 1 | 1999 | 33 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2018 | 53 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 15520 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 2219 | 0.160 |
Why?
|
| Computational Biology | 4 | 2017 | 3519 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2021 | 497 | 0.160 |
Why?
|
| Exanthema | 1 | 2023 | 501 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13104 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 4751 | 0.160 |
Why?
|
| Survival Rate | 7 | 2018 | 12788 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2016 | 10252 | 0.150 |
Why?
|
| DNA Repair | 1 | 2007 | 2046 | 0.150 |
Why?
|
| Cohort Studies | 11 | 2023 | 40559 | 0.150 |
Why?
|
| Phenylenediamines | 1 | 2018 | 90 | 0.150 |
Why?
|
| Health Education | 3 | 2017 | 1056 | 0.150 |
Why?
|
| Skin Diseases, Viral | 1 | 1997 | 21 | 0.150 |
Why?
|
| Sampling Studies | 1 | 2019 | 623 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2000 | 297 | 0.150 |
Why?
|
| Patient Selection | 1 | 2009 | 4216 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1265 | 0.150 |
Why?
|
| Melanoma, Amelanotic | 1 | 2016 | 19 | 0.150 |
Why?
|
| Metalloproteins | 1 | 2017 | 100 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3020 | 0.150 |
Why?
|
| Exons | 5 | 2013 | 2439 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2020 | 673 | 0.140 |
Why?
|
| Cancer Vaccines | 2 | 2015 | 1023 | 0.140 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2017 | 100 | 0.140 |
Why?
|
| Fibroblasts | 2 | 2020 | 4162 | 0.140 |
Why?
|
| Age of Onset | 4 | 2018 | 3270 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2007 | 9647 | 0.140 |
Why?
|
| Mass Screening | 4 | 2020 | 5253 | 0.140 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 14723 | 0.140 |
Why?
|
| Germ Cells | 1 | 2020 | 631 | 0.140 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2019 | 375 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 5867 | 0.140 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 237 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1998 | 473 | 0.140 |
Why?
|
| Alleles | 4 | 2018 | 6933 | 0.130 |
Why?
|
| Protein Kinases | 3 | 1992 | 1640 | 0.130 |
Why?
|
| Lymphoma | 1 | 2004 | 1877 | 0.130 |
Why?
|
| Minocycline | 1 | 1996 | 163 | 0.130 |
Why?
|
| Psoriasis | 2 | 2017 | 902 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2017 | 463 | 0.130 |
Why?
|
| Mosaicism | 2 | 2008 | 441 | 0.130 |
Why?
|
| Cell Movement | 2 | 2019 | 5218 | 0.130 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 360 | 0.130 |
Why?
|
| Color | 1 | 2016 | 307 | 0.130 |
Why?
|
| Algorithms | 6 | 2016 | 13882 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 2213 | 0.120 |
Why?
|
| Butadienes | 2 | 2011 | 110 | 0.120 |
Why?
|
| Melanins | 1 | 2016 | 289 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 1997 | 264 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 19905 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 247 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 625 | 0.120 |
Why?
|
| Dermatomyositis | 1 | 1997 | 224 | 0.120 |
Why?
|
| Radiation Protection | 1 | 1998 | 419 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 2727 | 0.120 |
Why?
|
| Membrane Glycoproteins | 3 | 2011 | 3771 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2001 | 934 | 0.120 |
Why?
|
| Comet Assay | 1 | 2013 | 71 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 261 | 0.120 |
Why?
|
| United States | 11 | 2021 | 69872 | 0.120 |
Why?
|
| Gene Expression | 2 | 2019 | 7798 | 0.120 |
Why?
|
| Retrospective Studies | 17 | 2023 | 77460 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2018 | 3689 | 0.110 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2012 | 303 | 0.110 |
Why?
|
| Adolescent | 15 | 2020 | 85779 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 944 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 657 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2018 | 1063 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2017 | 12207 | 0.110 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 581 | 0.110 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 853 | 0.110 |
Why?
|
| Carcinoma | 1 | 2004 | 2375 | 0.110 |
Why?
|
| Cells, Cultured | 5 | 2020 | 19233 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 3707 | 0.110 |
Why?
|
| RNA | 1 | 2022 | 2749 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 331 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 3 | 2010 | 1525 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1660 | 0.110 |
Why?
|
| Clone Cells | 1 | 2016 | 1692 | 0.110 |
Why?
|
| Hair Color | 1 | 2013 | 136 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 2938 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2006 | 2282 | 0.110 |
Why?
|
| Karyopherins | 1 | 2013 | 137 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2015 | 3476 | 0.110 |
Why?
|
| Massachusetts | 4 | 2015 | 8662 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2008 | 4687 | 0.110 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 1032 | 0.100 |
Why?
|
| Greece | 2 | 2018 | 344 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1410 | 0.100 |
Why?
|
| Young Adult | 12 | 2021 | 56429 | 0.100 |
Why?
|
| Time Factors | 7 | 2021 | 40075 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 2126 | 0.100 |
Why?
|
| Age Factors | 5 | 2019 | 18373 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2012 | 12961 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1434 | 0.100 |
Why?
|
| Base Sequence | 4 | 2012 | 12797 | 0.100 |
Why?
|
| Syndrome | 2 | 2012 | 3252 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 7282 | 0.100 |
Why?
|
| Consensus | 1 | 2020 | 2960 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 21833 | 0.100 |
Why?
|
| Telomere | 2 | 2016 | 910 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 8642 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 8949 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1941 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 323 | 0.090 |
Why?
|
| Skull Base Neoplasms | 1 | 2014 | 284 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 12073 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2015 | 2297 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 2887 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2013 | 1341 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2016 | 828 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2016 | 1865 | 0.090 |
Why?
|
| Nitriles | 2 | 2011 | 955 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3508 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 954 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 2504 | 0.080 |
Why?
|
| Genes, Retinoblastoma | 1 | 2009 | 136 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2013 | 1794 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2021 | 2267 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 499 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 399 | 0.080 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2012 | 372 | 0.080 |
Why?
|
| Cell Line | 4 | 2019 | 16000 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12356 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2018 | 2575 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 871 | 0.080 |
Why?
|
| Penetrance | 1 | 2010 | 381 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2015 | 9849 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1903 | 0.080 |
Why?
|
| Brachytherapy | 1 | 1996 | 1248 | 0.080 |
Why?
|
| Child | 10 | 2018 | 77709 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 3143 | 0.080 |
Why?
|
| Microspheres | 1 | 2010 | 777 | 0.080 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 175 | 0.080 |
Why?
|
| Eye | 1 | 2012 | 729 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2011 | 1342 | 0.080 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2010 | 39 | 0.080 |
Why?
|
| MART-1 Antigen | 2 | 2010 | 64 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 195 | 0.080 |
Why?
|
| Genetics, Medical | 1 | 2010 | 338 | 0.070 |
Why?
|
| Genome-Wide Association Study | 4 | 2017 | 12262 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12244 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 738 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 1624 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2014 | 1904 | 0.070 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2006 | 23 | 0.070 |
Why?
|
| Prevalence | 2 | 2019 | 15221 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 62 | 0.070 |
Why?
|
| Codon | 2 | 1999 | 611 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2011 | 749 | 0.070 |
Why?
|
| Ribonuclease III | 1 | 2008 | 275 | 0.070 |
Why?
|
| Sarcoma | 1 | 2018 | 1897 | 0.070 |
Why?
|
| Founder Effect | 1 | 2007 | 189 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2007 | 321 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 677 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 2700 | 0.070 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 57776 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2014 | 8436 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2076 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 2943 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1990 | 1085 | 0.060 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1262 | 0.060 |
Why?
|
| Cell Division | 3 | 2003 | 4569 | 0.060 |
Why?
|
| DNA | 3 | 2022 | 7294 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1580 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 281 | 0.060 |
Why?
|
| Phototherapy | 1 | 2008 | 377 | 0.060 |
Why?
|
| Ontario | 1 | 2005 | 383 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2008 | 436 | 0.060 |
Why?
|
| Health Care Costs | 1 | 1998 | 3208 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 1990 | 878 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2008 | 453 | 0.060 |
Why?
|
| Enzyme Activation | 5 | 2012 | 3702 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2004 | 3480 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2010 | 1534 | 0.060 |
Why?
|
| Antigens, Neoplasm | 3 | 2011 | 1988 | 0.060 |
Why?
|
| New South Wales | 1 | 2003 | 66 | 0.060 |
Why?
|
| Research Design | 2 | 2017 | 5984 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2005 | 6171 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 21748 | 0.060 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 468 | 0.060 |
Why?
|
| Survivors | 2 | 2006 | 2291 | 0.060 |
Why?
|
| Models, Biological | 2 | 2013 | 9584 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 674 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2011 | 2499 | 0.050 |
Why?
|
| Valine | 1 | 2004 | 413 | 0.050 |
Why?
|
| Vanadates | 2 | 1992 | 82 | 0.050 |
Why?
|
| Muscle, Smooth | 2 | 1997 | 934 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2740 | 0.050 |
Why?
|
| Methionine | 1 | 2004 | 590 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18034 | 0.050 |
Why?
|
| Pilomatrixoma | 1 | 2001 | 23 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4189 | 0.050 |
Why?
|
| Computer Graphics | 1 | 2003 | 361 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2018 | 41005 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2009 | 2307 | 0.050 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2001 | 39 | 0.050 |
Why?
|
| Heterozygote | 1 | 2008 | 2804 | 0.050 |
Why?
|
| Dermatofibrosarcoma | 1 | 2001 | 63 | 0.050 |
Why?
|
| Interferons | 1 | 2005 | 706 | 0.050 |
Why?
|
| Hair Diseases | 1 | 2001 | 74 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2007 | 2634 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 676 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2013 | 2962 | 0.050 |
Why?
|
| Gardner Syndrome | 1 | 2000 | 4 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11486 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2000 | 46 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 13286 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3616 | 0.040 |
Why?
|
| Transfection | 1 | 2008 | 5895 | 0.040 |
Why?
|
| Genes, APC | 1 | 2000 | 159 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 18111 | 0.040 |
Why?
|
| RNA Interference | 1 | 2008 | 2890 | 0.040 |
Why?
|
| Bradykinin | 2 | 1997 | 214 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 1998 | 1226 | 0.040 |
Why?
|
| Receptors, Bradykinin | 2 | 1997 | 19 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2001 | 252 | 0.040 |
Why?
|
| Proteomics | 2 | 2014 | 3638 | 0.040 |
Why?
|
| Genes, X-Linked | 1 | 2019 | 128 | 0.040 |
Why?
|
| Forecasting | 1 | 2008 | 2951 | 0.040 |
Why?
|
| Oxidoreductases | 2 | 2011 | 424 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6539 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2018 | 3587 | 0.040 |
Why?
|
| Lentigo | 1 | 1998 | 37 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 7182 | 0.040 |
Why?
|
| Heredity | 1 | 2018 | 154 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2000 | 399 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1101 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 39052 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 669 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1530 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1999 | 417 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1998 | 287 | 0.040 |
Why?
|
| Sunscreening Agents | 1 | 1998 | 132 | 0.040 |
Why?
|
| Injections | 1 | 2000 | 840 | 0.040 |
Why?
|
| Censuses | 1 | 1998 | 200 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2004 | 6621 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 20824 | 0.040 |
Why?
|
| Kinetics | 4 | 1995 | 6476 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 1641 | 0.040 |
Why?
|
| Risk | 1 | 2009 | 9688 | 0.040 |
Why?
|
| Phospholipases A | 1 | 1997 | 216 | 0.040 |
Why?
|
| Chickenpox | 1 | 1997 | 131 | 0.040 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 1996 | 24 | 0.030 |
Why?
|
| Vaccines | 1 | 2005 | 823 | 0.030 |
Why?
|
| Medical Records | 1 | 2002 | 1413 | 0.030 |
Why?
|
| Ear | 1 | 2016 | 173 | 0.030 |
Why?
|
| Sunlight | 1 | 1998 | 325 | 0.030 |
Why?
|
| Hospital Charges | 1 | 1998 | 362 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 1998 | 684 | 0.030 |
Why?
|
| Chromosome Mapping | 3 | 1999 | 4740 | 0.030 |
Why?
|
| Arm | 1 | 1999 | 589 | 0.030 |
Why?
|
| Recurrence | 2 | 2005 | 8340 | 0.030 |
Why?
|
| Technology, Radiologic | 1 | 1996 | 163 | 0.030 |
Why?
|
| Colonic Neoplasms | 2 | 1998 | 2542 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2000 | 1525 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1997 | 387 | 0.030 |
Why?
|
| Biophysical Phenomena | 1 | 1996 | 327 | 0.030 |
Why?
|
| Self-Examination | 1 | 2015 | 70 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 220 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1997 | 658 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 13814 | 0.030 |
Why?
|
| Software | 1 | 2009 | 4441 | 0.030 |
Why?
|
| Multigene Family | 1 | 1998 | 1102 | 0.030 |
Why?
|
| Biophysics | 1 | 1996 | 383 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2000 | 1117 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 1999 | 749 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1420 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2020 | 853 | 0.030 |
Why?
|
| Phosphatidylinositols | 1 | 1995 | 291 | 0.030 |
Why?
|
| Eye Enucleation | 1 | 2014 | 128 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 821 | 0.030 |
Why?
|
| Models, Economic | 1 | 1998 | 712 | 0.030 |
Why?
|
| Trachea | 2 | 1997 | 1076 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 103 | 0.030 |
Why?
|
| Fluorescence | 1 | 2016 | 751 | 0.030 |
Why?
|
| Australia | 2 | 2007 | 1167 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 4328 | 0.030 |
Why?
|
| Physicians, Family | 1 | 2015 | 345 | 0.030 |
Why?
|
| Pediatrics | 1 | 2008 | 3475 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 10183 | 0.030 |
Why?
|
| Probability | 1 | 1998 | 2506 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 2682 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1680 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2000 | 2751 | 0.030 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2011 | 19 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 1991 | 33 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 1991 | 24 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1991 | 67 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 1316 | 0.030 |
Why?
|
| Agouti Signaling Protein | 1 | 2011 | 21 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1992 | 2255 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1992 | 200 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 588 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2011 | 109 | 0.020 |
Why?
|
| Employment | 1 | 1998 | 1132 | 0.020 |
Why?
|
| Nail Diseases | 1 | 2011 | 51 | 0.020 |
Why?
|
| Dactinomycin | 1 | 1991 | 318 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 83 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2011 | 117 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 627 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 1970 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2011 | 155 | 0.020 |
Why?
|
| Diphenylamine | 1 | 2010 | 50 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 2015 | 3531 | 0.020 |
Why?
|
| Logistic Models | 1 | 2005 | 13409 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2000 | 6896 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 252 | 0.020 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2010 | 36 | 0.020 |
Why?
|
| Methotrexate | 1 | 1997 | 1728 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2012 | 63107 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 109 | 0.020 |
Why?
|
| Public Health | 1 | 2023 | 2602 | 0.020 |
Why?
|
| Carbazoles | 1 | 1991 | 226 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2011 | 290 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2018 | 2488 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 414 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 549 | 0.020 |
Why?
|
| Telangiectasis | 1 | 2009 | 76 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 840 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2004 | 7730 | 0.020 |
Why?
|
| Income | 1 | 1998 | 1913 | 0.020 |
Why?
|
| Binding Sites | 1 | 1998 | 6111 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2011 | 348 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5263 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 2006 | 2256 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 551 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 25039 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 328 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 592 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 1025 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 99 | 0.020 |
Why?
|
| Pheochromocytoma | 1 | 1990 | 337 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 1996 | 2480 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 890 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 3282 | 0.020 |
Why?
|
| Brain Neoplasms | 2 | 2000 | 8861 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1998 | 2616 | 0.020 |
Why?
|
| Americas | 1 | 2007 | 111 | 0.020 |
Why?
|
| Scotland | 1 | 2007 | 155 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 711 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2011 | 810 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1990 | 1802 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7785 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2010 | 880 | 0.020 |
Why?
|
| Terminal Care | 1 | 1998 | 1694 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 5974 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 972 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 2441 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 1031 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 2234 | 0.020 |
Why?
|
| Glioma | 1 | 2000 | 3401 | 0.020 |
Why?
|
| Neurofibromatosis 1 | 1 | 2010 | 570 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 740 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 1257 | 0.020 |
Why?
|
| Proteome | 1 | 2014 | 1798 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4201 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 1379 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 802 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 1572 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 9735 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 6100 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 11366 | 0.010 |
Why?
|
| Heparin | 1 | 1990 | 1637 | 0.010 |
Why?
|
| North America | 1 | 2006 | 1249 | 0.010 |
Why?
|
| Registries | 1 | 2018 | 8091 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9384 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 2839 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 9145 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 2007 | 0.010 |
Why?
|
| Dogs | 2 | 1997 | 3912 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4262 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2779 | 0.010 |
Why?
|
| Culture Media | 1 | 2002 | 909 | 0.010 |
Why?
|
| Medicare | 1 | 1998 | 6566 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2002 | 755 | 0.010 |
Why?
|
| Europe | 1 | 2006 | 3338 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 3611 | 0.010 |
Why?
|
| Neutrophils | 1 | 2011 | 3721 | 0.010 |
Why?
|
| Cheek | 1 | 1998 | 63 | 0.010 |
Why?
|
| Bucladesine | 1 | 1997 | 121 | 0.010 |
Why?
|
| Aluminum Compounds | 1 | 1997 | 51 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 1997 | 203 | 0.010 |
Why?
|
| Saponins | 1 | 1997 | 50 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3508 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 1997 | 180 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15078 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 15535 | 0.010 |
Why?
|
| Fluorides | 1 | 1997 | 127 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2000 | 53290 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 1995 | 111 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1995 | 114 | 0.010 |
Why?
|
| Enzyme Inhibitors | 2 | 1997 | 3799 | 0.010 |
Why?
|
| Cricetinae | 1 | 1999 | 2475 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1997 | 590 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1997 | 491 | 0.010 |
Why?
|
| Staurosporine | 1 | 1995 | 251 | 0.010 |
Why?
|
| Alkaloids | 1 | 1995 | 190 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1995 | 682 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 24252 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1997 | 1472 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1992 | 306 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1992 | 331 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 2120 | 0.010 |
Why?
|
| Receptor, trkA | 1 | 1992 | 164 | 0.010 |
Why?
|
| Adenine | 1 | 1997 | 936 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1992 | 480 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2006 | 6542 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1992 | 489 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1995 | 1227 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1801 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1995 | 3001 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 10943 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 35425 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2736 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 7914 | 0.000 |
Why?
|